REFERENCES
- Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., (2010). Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. The Journal of Pharmacology and Experimental Therapeutics, 334, 171–181.
- Kay S. R, Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.
- Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology, 28, 519–526.
- Meltzer, H. Y., Cucchiaro, J., Silva, R., Ogasa, M., Phillips, D., Xu, J., Kalai, A. H., Schweizer, E., Pikalov, A., & Loebel, A. (2011). Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine-controlled study. American Journal of Psychiatry, 168(9), 957–967.
- Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., & Loebel, A. (2009). Lurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 70(6), 829–836.
- Stahl, S. M. (2010). The serotonin-7 receptor as a novel therapeutic target. The Journal of Clinical Psychiatry, 71(11), 1414–1415.
- Sunovion. (2010). Latuda (lurasidone): Full prescribing information. Retrieved from http://www.latuda.com/latudaprscribinginformation.pdf
- Tandon, R. (2002). Safety and Tolerability: How Do Newer Generation “Atypical” Antipsychotics Compare? Psychiatric Quarterly, 73(4), 297–311.